Jeffrey Bornstein
CMO Mediar Therapeutics
Dr. Jeffrey Bornstein is a seasoned biopharmaceutical executive and physician-scientist currently serving as Chief Medical Officer of Mediar Therapeutics, a company pioneering novel therapies for fibrotic diseases. With over 20 years of leadership experience across all phases of drug development, he specializes in translating innovative science into clinical programs for fibrotic disorders.
Previously, Dr. Bornstein served as CMO of Eledon Pharmaceuticals (2021-2023) and held senior roles at Takeda (VP, Head of Clinical Sciences, GI Division), Biogen, and Gilead Sciences, where he led several liver and lung fibrosis development programs. His career spans executive positions at multiple biotechs including Ocera Therapeutics and Tioga Pharmaceuticals, building an exceptional track record in drug development.
Trained in internal medicine with subspecialities in GI and hepatology and with faculty experience at Duke University Medical Center, Dr. Bornstein combines deep clinical expertise with strategic development acumen to advance transformative treatments for fibrotic conditions.
Seminars
As antifibrotic developers aim to intervene earlier in disease, traditional endpoints such as FVC, eGFR, biopsy, and long-term clinical outcomes may be too slow, invasive, or insensitive to demonstrate early therapeutic benefit. This workshop will explore how biomarker, imaging, and endpoint strategies can be integrated to detect antifibrotic efficacy sooner, enrich the right patients, and build confidence in early proof of disease modification.
Discussion Topics Include:
- Integrating multi-omic approaches combining proteomics, spatial transcriptomics, and single-cell sequencing to capture the complexity of fibrotic disease progression, improving trial success rates and accelerating paths to approval
- Defining what earlier proof of antifibrotic efficacy should look like across lung, kidney, liver, gut, and skin fibrosis, and where traditional endpoints such as FVC, eGFR, biopsy, and long-term outcomes fall short
- Evaluating how circulating biomarkers, imaging, digital pathology, collagen turnover markers, and molecular signatures can be integrated to detect treatment response earlier
- Utilizing non-invasive biomarker strategies including blood-based assays and advanced imaging to enable frequent longitudinal monitoring, improving patient recruitment and retention while detecting drug activity with greater sensitivity
- Navigating regulatory hurdles in endpoint acceptance
